Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 95
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 11 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Tirzepatide improves weight loss in type 1 diabetes and obesity
Última actualización 18 de julio de 2026
Key finding
Mean change in weight was -10.3 kg (95% CI -12.8 to -7.7 kg) in the tirzepatide group.
This Phase 2 trial evaluated tirzepatide in adults with type 1 diabetes and obesity, showing significant weight loss and insulin dose reduction.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This Phase 2 trial evaluated tirzepatide in adults with type 1 diabetes and obesity, showing significant weight loss and insulin dose reduction.
Clinical relevance
These findings are clinically significant as they suggest that tirzepatide could be an effective treatment option for managing obesity in adults with type 1 diabetes, potentially improving metabolic control and reducing the burden of insulin therapy.
Keep in mind
Non-randomized design limits causal inferences. Sample size and demographic characteristics may affect generalizability. Short duration of follow-up may not capture long-term effects.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Jennifer RS, Ruth F, Dorit S, Jerry RG. Tirzepatide in Adults with Type 1 Diabetes and Obesity: A Phase 2 Trial. Diabetes Care. 2026;49(1):161-170. doi:10.2337/dc25-2379
Efectos Principales
Mean weight loss of -10.3 kg in the tirzepatide group (p=0.0001).
100% of tirzepatide participants achieved weight loss of ≥5%.
Total daily insulin dose decreased by -24.2 units/day in the tirzepatide group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Body weight, HbA1c, Proportion of participants achieving weight loss of 5% or more at 52 weeks, and 2 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Body weight
- HbA1c
- Proportion of participants achieving weight loss of 5% or more at 52 weeks
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
5
Evidence pairs
546
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Insulin Resistance
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 12 estudios
Add to Evidence TrackerProportion of participants achieving weight loss of 5% or more at 52 weeks
Tirzepatide → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Tirzepatide → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerTotal daily insulin dose
Tirzepatide → Total daily insulin dose
Tirzepatide → Total daily insulin dose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerWeight loss of 10% or more at 52 weeks
Tirzepatide → Weight loss of 10% or more at 52 weeks
Tirzepatide → Weight loss of 10% or more at 52 weeks
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Tirzepatide led to a significant weight loss of -10.3 kg.
- All participants on tirzepatide lost at least 5% of their body weight.
- Insulin doses decreased by -24.2 units/day with tirzepatide.
A quién se aplica
- Adults with type 1 diabetes.
- Individuals with obesity.
Tener en Cuenta
- Results may not apply to non-obese individuals or those with type 2 diabetes.
- Further studies are needed to confirm long-term safety and efficacy.
- The trial's non-randomized design may introduce bias.
Entre Líneas
- Non-randomized design limits causal inferences.
- Sample size and demographic characteristics may affect generalizability.
- Short duration of follow-up may not capture long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 12 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 95
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 11 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
12 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
12 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
11 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
12 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
11 results
All studies on Tirzepatide
Intervention: Tirzepatide
12 results
All studies measuring HbA1c
Outcome: HbA1c
12 results
All studies measuring Body weight
Outcome: Body weight
11 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.9 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 83.3 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve insulin resistance?
Strong Evidence
GLP-1 Receptor Agonists may improve Insulin Resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Total daily insulin dose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 6 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Tirzepatide affect proportion of participants achieving weight loss of 5% or more at 52 weeks?
Emerging Evidence
Tirzepatide appears to improve Proportion of participants achieving weight loss of 5% or more at 52 weeks.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Proportion of participants achieving weight loss of 5% or more at 52 weeks
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Tirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesDietary interventions improve glycemic control in pre-diabetic patientsSwitching to tirzepatide from dulaglutide improved HbA1c and weight across baseline characteristics
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.